CAS: 8050-81-5; Simethicone

专利信息

专利号:EP-2465936-A1
优先权日:2010-12-20
标题 :Enzymatic synthesis of statins and intermediates thereof
权利人:LEK PHARMACEUTICALS
摘要:The present invention discloses a process for preparing an active pharmaceutical ingredient (API) or intermediates thereof, notably particular step in the synthesis of an intermdiate useful for example in the preparation of statins, by using an enzyme capable of catalyzing oxidation or dehydrogenation. The invention further provides an expression system effectively translating said enzyme. In addition, the invention relates to a specific use of such enzyme for preparing API or intermediate thereof, and in particular for preparing statin or interemediate thereof.

专利号:US-11325888-B2
优先权日:2017-08-11
标 题:Method for the synthesis of monoprotected bifunctional prodrugs and antibody drug conjugates based thereon as well as a method for preparing antibody drug conjugates
发明人：TIETZE LUTZ F
权利人:GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS
摘要:The present invention relates to a method for the synthesis of compounds useful in the preparation of antibody drug conjugates (ADC), namely, monoprotected dimeric bifunctional prodrugs based on duocarmycin analogs. In a further aspect, compounds obtained by the method according to the present invention are provided. The monoprotected bifunctional prodrug is used for preparing antibody drug conjugates composed of an antibody moiety and the monoprotected bifunctional prodrug. The antibody compound conjugates thus obtained are provided. Further, a method of preparing an antibody drug conjugate composed of two identical or two different antibody moieties is provided as well as the antibody compound conjugate containing two different antibody moieties accordingly. These conjugates can be used in pharmaceutical compositions, in particular, for use in treatment of tumors, e.g. for use in ADC therapy.

专利号:US-11717498-B2
优先权日:2013-12-31
标题 :Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
发明人：POPP KARL; MECKLER HAROLD
权利人:Chemapotheca LLC; PHARMAPOTHECA A INC
摘要:The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

专利号:US-6777554-B2
优先权日:2001-02-05
标题 :Preparation of N-methylparoxetine and related intermediate compounds
发明人：FINKELSTEIN NINA
权利人:TEVA PHARMA
摘要:The present invention provides a process for preparing N-methylparoxetine, an intermediate in the synthesis of paroxetine, by reacting sesamol-tetrabutylammonium salt with CIPMA. The present invention is not limited to the synthesis of N-methylparoxetine, but also includes other similar compounds.

专利号:US-11850220-B2
优先权日:2020-05-19
标题 :Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
发明人：PANDA SIVA
权利人:UNIV RES INST INC AUGUSTA
摘要:Disclosed herein as ibuprofen hybrid conjugates and methods of their use to reduce inflammation, pain, and fever. The ibuprofen conjugates have potent anti-inflammatory and analgesic properties with low potential for ulcerogenic activity. An exemplary compound is an ibuprofen-amino acid-4-aminophenol hybrid. Also disclosed are methods of treating or reducing inflammation, pain, and fever in a subject.

专利号:US-9567430-B2
优先权日:2011-12-02
标 题 :Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
发明人：SALTZMAN W MARK; JIANG ZHAOZHONG; ZHOU JIANGBING; LIU JIE
权利人:UNIV YALE
摘要:Poly(amine-co-ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the nanoparticles are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.